Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of GCC Agonists for cGMP Signal in Duodenal Tissue
NCT05107219Phase 1Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Nov 2022
- Primary completion
- Feb 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of plecanatide and linaclotide (3 arms), sponsored by University of Wisconsin–Madison. Primary endpoint: Cyclic guanosine monophosphate levels at 2 years. Started Nov 2022; status: completed.
02
Drugs
plecanatidelinaclotide
Beyond the preview
Go deeper on NCT05107219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05107219.